Ge W, et al. - Researchers examined the data to validate the novel 4-gene prognostic signature for hypermutated colorectal cancer from The Cancer Genome Atlas (TCGA) as a validation data set. A 4-gene signature (ACVR2A, APC, DOCK2, and POLE) was constructed with training in 45 hypermutated cases at Zhejiang University (ZJU) and validation in 24 hypermutated subjects from TCGA. They noticed poor survival in the high-risk group. They also compared the prognostic signature with other risk factors like microsatellite instability (MSI) status, POLE driver mutation, BRAF-p.V600E, tumor mutational burden, and TNM staging.